Cul­li­nan On­col­o­gy goes full cir­cle, scor­ing $275M for shar­ing the load on EGFR in­hibitor with orig­i­nal de­vel­op­er

On­ly a few months af­ter CEO Nadim Ahmed came over from Bris­tol My­ers Squibb and joined as the top brass at the can­cer-fo­cused biotech Cul­li­nan On­col­o­gy, the sec­ond half of a ma­jor deal has fi­nal­ly clicked in­to place — giv­ing Cul­li­nan a well-timed $275 mil­lion.

The Mass­a­chu­setts biotech an­nounced ear­ly Thurs­day morn­ing that it has com­plet­ed Part II of a deal with Japan­ese biotech Tai­ho Phar­ma­ceu­ti­cal that orig­i­nal­ly start­ed back in 2019 — cul­mi­nat­ing in a co-com­mer­cial­iza­tion and co-de­vel­op­ment part­ner­ship for CLN-081, a ty­ro­sine ki­nase in­hibitor can­di­date be­ing in­ves­ti­gat­ed for NSCLC with a spe­cif­ic type of mu­ta­tion al­ready pur­sued by at least two phar­ma gi­ants: EGFR ex­on 20.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER